At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Woyach et al presented findings from the multicenter Alliance for Clinical Trials in Oncology A041702 trial, which was designed to evaluate if the triplet of ibrutinib, obinutuzumab, and venetoclax with response-guided discontinuation of ibrutinib improves survival vs ibrutinib and obinutuzumab with indefinite ibrutinib in treatment-naive, older patients with chronic lymphocytic leukemia (CLL) (Abstract 7500).
